|
Management
Board of Advisors
Board of Scientific Advisors
|
 |
|
|
Karl-Erik Andersson, MD PhD
Professor of Clinical Pharmacology, Department of Clinical
Pharmacology, University of Lund, Lund, Sweden
Karl-Erik Andersson is since 1978 Professor and Chairman of the Department of Clinical Pharmacology, University of Lund, Lund, Sweden. He received his medical degree from the University of Lund in 1968, where he subsequently worked as a lecturer in Clinical Pharmacology. In 1975 he completed a Swedish specialist degree in Internal Medicine and was appointed as Professor of Clinical Pharmacology at the University of Odense, Denmark. From 1976 to 1978 he had the same position at the University of Aarhus, Denmark. He has been visiting professor at the Department of Obstetrics and Gynaecology, University of Toronto (1983-1985), and at the Department of Urology, University of Virginia, Charlottesville, USA (1997-1998). From 1993 to 2000 Professor Andersson was elected Research Dean of the Medical Faculty at the University of Lund. Professor Andersson’s research interests include urogenital and cardiovascular pharmacology and physiology. He is a member of many international societies including the American Urological Association, the European Association of Urology, and the International Society for Sexual and Impotence Research. He also serves on the Editorial Boards of several journals including Urology, European Urology, British Journal of Urology, Neurourology and Urodynamics, International Journal of Impotence Research, and British Journal of Pharmacology. During his career, Professor Andersson has authored more than 600 articles in peer-reviewed international journals.
|
|
Stephen Archer, MD, FRCPC, FAHA
University of Alberta Hospital, Edmonton, Canada
Stephen Archer is a clinician-scientist working in O2-sensing, cellular electrophysiology, endothelial function, and potassium channels. He is currently Professor of Medicine and Physiology and the Director of the Division of Cardiology at the University of Alberta in Edmonton, Alberta, Canada. After graduating from Queen's University (MD, 1981) and completing an internship at the Royal Columbian Hospital in Vancouver, he trained in internal medicine and cardiology training at the University of Minnesota. In 1988 he joined the cardiology faculty at the University of Minnesota and became director of the echocardiography laboratory at the Minneapolis Veterans Affairs Medical Centre. In 1998 he became a Professor of Medicine at the University of Minnesota. Subsequently, he returned to Canada as Professor of Medicine and Physiology at the University of Alberta. Dr. Archer directs the Division of Cardiology, heads the Vascular Biology Research Group and hold the Heart and Stroke Chair for Cardiovascular Research. Dr. Archer is on the Editorial Board of Circulation Research. Dr. Archer has received numerous awards. In 1996-1997 he was the Visiting Professor in Physiology for the French Physiological Society. He received of the Gold Medal in Medicine from Queen’s University (1981) and the Paul Armstrong Research Achievement Award from the University of Alberta (2002).
|
 |
Dr. Mark T. Nelson
Professor: Departments of Pharmacology (Chair) & Physiology, University of Vermont
Dr. Nelson is a world-renowned smooth muscle physiologist/ pharmacologist. The overall goal of the research in Dr. Nelson's laboratory is to understand the control of smooth muscle cell function by the cell membrane. A combined approach, utilizing single cell isolation, single channel and macroscopic recording techniques, intracellular calcium and calcium spark measurements using conventional fluorescent imaging techniques, laser scanning, and confocal microscopy, diameter and membrane potential measurements in intact pressurized arteries, and expression of ion channels, is used to examine the properties of calcium and potassium channels and ryanodine-sensitive calcium release channels. Calcium and potassium channels are the sites of action of several types of drugs that are used to treat cardiovascular disorders such as hypertension and angina. To understand the mechanism of action of these important drugs, the effects of these agents on calcium and potassium channel behavior are being investigated.
|
|
